ZYBERNO
Stock Report
Updated Sep 1, 2026

THERIVA BIOLOGICS, INC. (TOVX)

Healthcare • NYSE

$0.25

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
THERIVA BIOLOGICS, INC. (TOVX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-93.5%)
Debt-to-Equity (Solvency Risk):GOOD (0.31x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-325.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

THERIVA BIOLOGICS, INC. (TOVX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TOVX generated -$18.64M in Owner Earnings. Reinvestment rate: 0.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.25
Market Cap:$11.43M

Valuation Multiples (3)

P/B Ratio:0.94x
P/S Ratio:9.53x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.99M

Price Action & Momentum (3)

Momentum Percentile:11 / 100
% of 52-Week High:28.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-32.7%
Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-2.7%

Margin Analysis (1)

Ebitda Margin:-987.1%

Yield Metrics (2)

Earnings Yield:-$964.91
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:96.7%
Latest Earnings Filed:2026-08-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.13x
Quick Ratio:1.13x
Cash Ratio:0.94x

Leverage Analysis (3)

Debt To Equity Ttm:0.31x
Debt-to-Equity Ratio:0.31x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,414.76x
Times Interest Earned:-1,414.76

Capital Structure (4)

Working Capital:1,560,000.00
Cash And Cash Equivalents:11,337,000.00
Long Term Debt:$1.37M
Net Debt:-$9.44M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$1.20M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$11.92M

Bottom Line Performance (3)

-$11.62M
Income Before Tax:-$11.62M
Ebitda Ttm:-11,845,000.00

Operating Expenses (5)

Operating Expenses:12,224,000.00
R And D Expense:5,306,000.00
Sga Expense:6,918,000.00
Income Tax Expense:-$94.00K
Interest Expense:17,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1,768.7%
Sga To Revenue Percentage:2,306.0%
Ebitda Margin:-987.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$34.86M
Current Assets:$13.67M
Ppe Net:1,175,000.00
Goodwill:0.00
Intangible Assets:$19.06M

Liability Structure (4)

Total Liabilities:22,670,000.00
Current Liabilities:12,111,000.00
Long Term Debt:$1.37M
Short Term Debt:$525.00K

Equity & Capital (3)

Equity:$12.19M
Retained Earnings:-$363.97M
Common Stock:350,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,418,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:135,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$14.37M-$18.66M

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$3.87M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$1.51M
Long Term Debt Repayments:$56.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:79,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.20
-$2.20
Earnings Per Share Ttm:-$0.25

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.03
Operating Cash Flow Per Share:-$0.36

Book Value & Capital (2)

Book Value Per Share:$0.27
Cash Per Share:0.25

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x
Working Capital Turnover Ttm:0.77x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:1,952.14
Cash Conversion Cycle:-3,950.14
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$18.64M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-2.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-37.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:TOVX
Company Name:THERIVA BIOLOGICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:45.89M
Shares Outstanding Basic:45.89M
Shares Outstanding Diluted:45.89M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 15:24:06 UTC
Data Timestamp:2026-08-21T15:30:26.393080
Scroll to Top